

ISOLAGEN INC  
Form 8-K  
February 03, 2004

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K  
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

**February 3, 2004**

Date of Report (date of Earliest Event Reported)

**ISOLAGEN, INC.**

(Exact Name of Registrant as Specified in its Charter)

**DELAWARE**

(State or Other Jurisdiction of  
Incorporation or Organization)

**0-12666**

(Commission File No.)

**87-0458888**

(I.R.S. Employer Identification No.)

**2500 Wilcrest, 5th Floor, Houston, Texas 77042**

(Address of principal executive offices and zip code)

**(713) 780-4754**

(Registrant's telephone number, including area code)

**Not applicable**

(Former name or former address, if changed from last report)

---

**TABLE OF CONTENTS**

SIGNATURE

EXHIBIT INDEX

Press Release - Announces Positive Results

**Item 5. Other Events.**

On February 3, 2004, the Company issued a press release relating to positive results in Phase I dental study. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The reader is advised to read the press release in its entirety.

**[THE SIGNATURE PAGE FOLLOWS.]**

---

**SIGNATURE**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ISOLAGEN, INC.**

Date: February 3, 2004

By: /s/ Jeffrey W. Tomz  
Chief Financial Officer

EXHIBIT INDEX

Exhibit 99.1

Press Release